REFERENCES

• GrantBF.HasinDS.StinsonFS.et al.The epidemiology of DSM-IV panic disorder and agoraphobia in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions.J Clin Psychiatry.20066736337416649821
   PubMed Web of Science ®Google Scholar
• PittsFM.McClureJN.Lactate metabolism in anxiety neurosis.N Engl J Med.1967277132913366081131
   PubMed Web of Science ®Google Scholar
• MillerFG.RosensteinDL.Psychiatric symptom-provoking studies: an ethical appraisal.Biol Psychiatry.1997424034099276080
   PubMed Web of Science ®Google Scholar
• NuttD.LawsonC.Panic attacks - a neurochemical overview of models and mechanisms.Br J Psychiatry.19921601651781540756
   PubMed Web of Science ®Google Scholar
• GutmacherLB.MurphyDL.InselTR.Pharmacological models of anxiety.Compr Psychiatry.1983243123266349923
   PubMed Web of Science ®Google Scholar
• GormanJM.FyerMR.LiebowitzMR.KleinDF.Pharmacologic provocation of panic attacks. In: Meltzer HY, ed.Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press 1987985998
   Google Scholar
• LiebowitzMR.CoplanJD.MartinezJ.et al.Effects of intravenous diazepam pretreatment on lactate-induced panic.Psychiatry Res.1995581271388570764
   PubMed Web of Science ®Google Scholar
• PohlR.BalonR.BerchouR.LycakiH.Lactate-induced anxiety after imipramine and diazepam treatment.Anxiety.1994154639160549
   PubMedGoogle Scholar
• CarrDB.SheehanDV.SurmanOS.et al.Neuroendocrine correlates of lactate-induced anxiety and their response to chronic alprazolam therapy.Am J Psychiatry.19861434834942869703
   PubMed Web of Science ®Google Scholar
• LiebowitzMR.FyerAJ.GormanJM.et al.Alprazolam in the treatment of panic disorders.J Clin Psychopharmacol.1986613202869059
   PubMed Web of Science ®Google Scholar
• CowleyDS.DagerSR.Roy-ByrnePP.AveryDH.DunnerDL.Lactate vulnerability after alprazolam versus placebo treatment of panic disorder.Biol Psychiatry.19913049561892962
   PubMed Web of Science ®Google Scholar
• RifkinA.KleinDF.DillonDJ.et al.Blockade by imipramine or desipramine of panic induced by sodium lactate.Am J Psychiatry.19811386766777235068
   PubMed Web of Science ®Google Scholar
• YeraganiVK.PohlR.BalonR.RaineyJM.BerchouR.OrtizA.Sodium lactate infusions after treatment with tricyclic antidepressants: behavioural and physiological findings.Biol Psychiatry.1988247677743067755
   PubMed Web of Science ®Google Scholar
• PolsH.ZandbergenJ.de LoofC.GriezE.Attenuation of carbon dioxide-induced panic after clonazapam treatment.Acta Psychiatr Scand.1991845855861792935
   PubMed Web of Science ®Google Scholar
• NardiAE.ValencaAM.NascimentoI.MezzasalmaMA.ZinWA.Doubleblind acute clonazepam vs placebo in carbon dioxide-induced panic attacks.Psychiatry Res.20009417918410808043
   PubMed Web of Science ®Google Scholar
• SandersonWC.WetzlerS.AsnisGM.Alprazolam blockade of CO2-provoked panic in patients with panic disorder.Am J Psychiatry.1994151122012228037259
   PubMed Web of Science ®Google Scholar
• WoodsSW.CharneyDS.DelgadoPL.HenningerGR.The effect of longterm imipramine treatment on carbon-dioxide-induced anxiety in panic disorder patients.J Clin Psychiatry.1990515055072175307
   PubMed Web of Science ®Google Scholar
• BertaniA.PernaG.ArancioC.CaldirolaD.BellodiL.Pharmacologic effect of imipramine, paroxetine, and sertraline on 35% carbon dioxide hypersensitivity in panic patients: a double-blind, random, placebo-controlled study.J Clin Psychopharmacol.1997179710110950471
   PubMed Web of Science ®Google Scholar
• PernaG.BertaniA.CaldirolaD.GabrieleA.CocchiS.BellodiL.Antipanic drug modulation of 35% CO2 hyperreactivity and short-term therapy outcome.J Clin Psychopharmacol.20022230030812006901
   PubMed Web of Science ®Google Scholar
• PolsHJ.HauzerRC.MeijerJA.VerburgK.GriezEJ.Fluvoxamine attenuates panic induced by 35% CO2 challenge.J Clin Psychiatry.1996575395428968304
   PubMed Web of Science ®Google Scholar
• BradwejnJ.KoszyckiD.Imipramine antagonism of the panicogenic effects of choiecystokinin tetrapeptide in panic disorder patients.Am J Psychiatry.19941512612638296900
   PubMed Web of Science ®Google Scholar
• ShlikJ.AluojaA.VasarV.VasarE.PodarT.BradwejnJ.Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide in patients with panic disorder.J Psychiatry Neurosci.1997223323409401314
   PubMed Web of Science ®Google Scholar
• Van MegenHJ.WestenbergHG.den BoerJA.SlaapB.ScheepmakersA.Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK4 induced panic attacks.Psychopharmacology.19971293573649085405
   PubMed Web of Science ®Google Scholar
• SevyS.BrownSL.WetzlerS.et al.Effects of alprazolam on increases in hormonal and anxiety levels induced by meta-chlorophenylpiperazine.Psychiatry Res.1994532192297870844
   PubMed Web of Science ®Google Scholar
• CharneyDS.HeningerGR.Noradrenergic function and the mechanism of action of antianxiety treatment. I. The effect of long-term alprazolam treatment.Arch Gen Psychiatry.1985424584672859008
   PubMed Web of Science ®Google Scholar
• CharneyDS.HeningerGR.Noradrenergic function and the mechanism of action of antianxiety treatment. II. The effect of long-term imipramine treatment.Arch Gen Psychiatry.1985424734812985014
   PubMed Web of Science ®Google Scholar
• GoddardAW.WoodsSW.SholomskasDE.GoodmanWK.CharneyDS.HeningerGR.Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induces anxiety in panic disorder.Psychiatry Res.1993481191338416022
   PubMed Web of Science ®Google Scholar
• BradwejnJ.KoszyckiD.Couëtouxdu Tertre A.van MegenH.den BoerJ.WestenbergH.The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder.Arch Gen Psychiatry.1994514864938192551
   PubMed Web of Science ®Google Scholar
• Van MegenHJGM.WestenbergHGM.den BoerJA.Effect of the cholecystokinin-B receptor antagonist L-365,260 on lactate-induced panic attacks in panic disorder patients.Biol Psychiatry.1996408048068894076
   PubMed Web of Science ®Google Scholar
• KramerMS.CutlerNR.BallengerJC.et al.A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder.Biol Psychiatry.1995374624667786960
   PubMed Web of Science ®Google Scholar
• WiedemannK.JahnH.YassouridisA.KellnerM.Anxiolytic-like effects of atrial natriuretic peptide on cholecystokinin-tetrapeptide-induced panic attacks: preliminary findings.Arch Gen Psychiatry.20015837137711296098
   PubMed Web of Science ®Google Scholar
• KellnerM.JahnH.WiedemannK.Natriuretic peptides and panic disorder: therapeutic prospects.Expert Rev Neurother2003338138619810905
   PubMedGoogle Scholar
• StröhleA.KellnerM.HolsboerF.WiedemannK.Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder.Am J Psychiatry.20011581514151611532742
   PubMed Web of Science ®Google Scholar
• KronenbergG.BergerP.TauberRF.BandelowB.HenkelV.HeuserI.Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin (NK3) receptor antagonist in panic disorder with pre- and post-treatment cholecystokinin tetrapeptide (CCK-4) challenges.Pharmacopsychiatry.200538242915706463
   PubMed Web of Science ®Google Scholar
• SchenbergLC.Towards a translational model of panic attack.Psychol Neurosci.20103937
   Google Scholar
• SinhaSS.GoetzRR.KleinDF.Physiological and behavioral effects of naloxone and lactate in normal volunteers with relevance to the pathophysiology of panic disorder.Psychiatry Res.200714930931417156855
   PubMed Web of Science ®Google Scholar
• PreterM.LeeSH.PetkovaE.VannucciM.KimS.KleinDF.Controlled cross-over study in normal subjects of naloxone-preceding-lactate infusions; respiratory and subjective responses: relationship to endogenous opioid system, suffocation false alarm theory and childhood parental loss.Psychol Med.20114138539320444308
   PubMed Web of Science ®Google Scholar
• BradwejnJ.KoszyckiD.ShriquiC.Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioural findings.Arch Gen Psychiatry.1991486036102069490
   PubMed Web of Science ®Google Scholar
• BradwejnJ.KoszyckiD.BourinM.Dose ranging study of the effects of choleystokinin in healthy volunteers.J Psychiatry Neurosci.19911691951911739
   PubMed Web of Science ®Google Scholar
• KoszyckiD.ZacharkoRM.Le MellédoMJ.BradwejnJ.Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers.Depress Anxiety.19988179750972
   PubMedGoogle Scholar
• GriezEJL.LousbergH.van den HoutMA.van der MolenGM.CO2 vulnerability in panic disorder.Psychiatry Res.19872087953107009
   PubMed Web of Science ®Google Scholar
• PernaG.BattagliaM.GarberiA.ArancioC.BertaniA.BellodiL.Carbon dioxide/oxygen challenge test in panic disorder.Psychiatry Res.1994521591717972572
   PubMed Web of Science ®Google Scholar
• ColosantiA.SalamonE.SchruersK.van DiestR.van DuinenM.GriezEJ.Carbon dioxide-induced emotion and respiratory symptoms in healthy volunteers.Neuropsychopharmacology.20083331933110
   Web of Science ®Google Scholar
• EserD.SchüleC.BagaiT.et al.Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study.Psychopharmacology.200732669680
   Google Scholar
• BaileyJE.PapdopoulosA.SeddonK.NuttDJ.A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO2 models of experimental human anxiety.J Psychopharmacol.20092311712218562427
   PubMed Web of Science ®Google Scholar
• CoryellW.RickelsH.Effects of escitalopram on anxiety and respiratory responses to carbon dioxide inhalation in subjects at high risk for panic disorder - a placebo-controlled, crossover study.J Clin Psychopharmacol.20092917417819512981
   PubMed Web of Science ®Google Scholar
• De MontignyC.Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings.Arch Gen Psychiatry.1989465115172730276
   PubMed Web of Science ®Google Scholar
• ZwanzgerP.EserD.AicherS.et al.Effects of alprazolam on choleystokinin-tetrapeptide-induced panic and hypothalamic-pituitaryadrenal-axis: a placebo-controlled study.Neuropsychopharmacology.20032897998412700707
   PubMed Web of Science ®Google Scholar
• SchunckT.MathisA.ErbG.et al.One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: Investigation of neural correlates with BOLDUK. J Psychopharmacol.2011255259
   PubMed Web of Science ®Google Scholar
• KellnerM.MuhtzC.DemiralayC.et al.The selective re-uptake inhibitor escitalopram modulates the panic response to cholecystokinin tetrapeptide in healthy man depending on 5-HTTLPR genotype.J Psychiatr Res.20094364264818930474
   PubMed Web of Science ®Google Scholar
• BradwejnJ.KoszyckiD.ParadisM.ReeceP.HintonJ.SedmanA.Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers.Biol Psychiatry.1995387427468580227
   PubMed Web of Science ®Google Scholar
• Van MegenHJ.WestenbergHC.den BoerJA.SlaapB.van Es-RadhakishunF.PandeAC.The cholecystokinin-B receptor antagonist CI988 failed to affect CCK-4 induced symptoms in panic disorder patients.Psychopharmacology.19971292432489084062
   PubMed Web of Science ®Google Scholar
• PandeAC.GreinerM.AdamsJB.LydiardRB.PierceMW.Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder.Biol Psychiatry19994686086210494457
   PubMed Web of Science ®Google Scholar
• KellnerM.MuhtzC.StarkK.YassouridisA.ArltJ.WiedemannK.Effects of a metabotropic glutamate (2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results.Psychopharmacology.200517931031515821951
   PubMed Web of Science ®Google Scholar
• Le MellédoJM.BradwejnJ.KoszyckiD.BichetDG.BellavanceF.The role of the beta-noradrenergic system in choleystokinin-tetrapeptide-induced panic symptoms.Biol Psychiatry.1998443643669755359
   PubMed Web of Science ®Google Scholar
• MunjackDJ.CrockerB.CabeD.et al.Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks.J Clin Psychopharmacol.1989922272651490
   PubMed Web of Science ®Google Scholar
• KhanS.LiberzonI.AbelsonJL.Effects of propranolol on symptom and endocrine responses to pentagastrin.Psychoneuroendocrinology.2004291163117115219640
   PubMed Web of Science ®Google Scholar
• ZwanzgerP.EserD.PadbergF.et al.Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers.Depress Anxiety.20031814014314625878
   PubMed Web of Science ®Google Scholar
• ZwanzgerP.EserD.NothdurfterC.et al.Effect of the GABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder.Pharmacopsychiatry.20094226626919924586
   PubMed Web of Science ®Google Scholar
• SheehanDV.SheehanKH.RajBA.JanavsJ.An open-label study of tiagabine in panic disorder.Psychopharmacol Bull.200740324018007567
   PubMedGoogle Scholar
• ZwanzgerP.BaghaiTC.SchueleC.et al.Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers.Neuropsychopharmacology.20012569970311682253
   PubMed Web of Science ®Google Scholar
• ZwanzgerP.RupprechtR.Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder.J Psychiatry Neurosci.20053016717515944741
   PubMed Web of Science ®Google Scholar
• RupprechtR.RammesG.EserD.et al.Translocator protein (18 kD) as a target for anxiolytics without benzodiazepine-like side effects.Science.200932549049319541954
   PubMed Web of Science ®Google Scholar
• MaronE.TóruI.TasaG.et al.Association testing of panic disorder candidate genes using CCK-4 challenge in healthy volunteers.Neurosci Lett.2008446889218832011
   PubMed Web of Science ®Google Scholar